Vaccine Milestones / Statuses – Pandemics in British Columbia

Timeline

See also the WHO’s timeline for the pandemic.

I estimated the approval dates in the section above based on the Pfizer and Moderna timelines or I found an official giving an estimate:

2020 Jan 11: COVID-19 gene sequence delivered to WHO.
2020 Feb 24: Moderna starts Phase 1 trial.
2020 July 27: Pfizer and Moderna Phase 3 trials started
2020 Nov 9: Pfizer announced their 95% prelim result
2020 Nov 18: Pfizer Phase 3 concluded
2020 Nov 20: Pfizer submits application to US FDA
2020 Nov 30: Novavax starts Phase 3 trials
2020 Nov 30: Moderna announced prelim results
2020 Dec 2: Moderna submits application to US FDA
2020 Dec 9: Pfizer EUA approved in Canada (135 days from start of Ph3, 19 days after US FDA submission)
2020 Dec 11: Pfizer EUA approved by FDA in USA
2020 Dec 19: Moderna EUA approved by FDA in USA
2020 Dec 23: Moderna approved in Canada (149 days from start of Ph3, 21 days after the US FDA submission)
2021 Jan 28: Novavax interim results
2021 Jan 29: Janssen interim results
2021 Feb 4: Janssen submits application to US FDA
2021 Feb 26: Canada approves AstraZeneca
2021 Feb 27: Janssen EUA approved by FDA in USA.
2021 Mar 5: Janssen approved in Canada
2021 Mar 11: Sanofi Ph2 trials started
2021 Mar 12: Novavax Ph3 trials in UK, South Africa done
2021 March 16: Medicago starts Ph3 trials
2021 Mar 16: Moderna doses the first children in study of under-12s.
2021 Apr 9: Pfizer submits application to US FDA for 12-15 year-olds
2021 May 5: Pfizer approved in Canada for 12-15 year-olds.
2021 May 10: Pfizer approved in the US for 12-15 year-olds.
2021 June 14: Novavax says that they really are done with Ph3.
2021 June 16: CureVac announces crappy Ph3 results.
2021 June 8: Pfizer announces that it’s about to start trial in children under 12.
2021 July 3: Pfizer announces a Phase 2 trial for a vax adapted for the Beta variant.
2021 Aug 27: Canada approves Moderna for kids over 12.
2021 September 1: Moderna asks the US FDA to approve its booster.
2021 September 10: Canada’s NACI recommends third dose mRNA for the immunocompromisedx.
2021 September 20: Pfizer announces that they have finished their trial for 5-12 year-olds.
2021 September 20: NDV-HXP-S, the Thai version of the HexaPro vaccine, finished Phase 1/2 with good results.
2021 September 21: The Washington University of St. Louis/Bharat Biotech nasal vaccine moves to Ph2/3.
2021 September 22: Clover announces good Ph3 results.
2021 September 23: US FDA approves booster for Pfizer.
2021 September 23: Novavax (and SII, who will manufacture it) says they are applying for approval from the World Health Organization.
2021 September 28: Pfizer submits preliminary data for 5-12 year-olds to the US FDA.
2021 September 28: Sanofi abandons its COVID-19 vax to focus on flu, COVID boosters.
2021 September 28: Canada’s NACI recommends third dose mRNA for the elderly.
2021 October 6: Moderna asks Health Canada to approve its booster.
2021 October 7: Pfizer requests that the US FDA approve its pediatric vaccination.
2021 October 7: Johnson & Johnson requests that the US FDA approve a booster.
2021 October 11: Novavax issues a preprint with their results. (So maybe they really are done with Phase 3 this time?)
2021 October 12: CureVac says they are abandoning their COVID-19 vaccine approval process and will focus on a second-gen product.
2021 October 15: Pfizer/BioNTech submit application to Health Canada for pediatric vaccine.
2021 October 18: Valneva announces good Ph3 results.
2021 October 21: CDC approves Moderna and J&J’s boosters.
2021 October 26: The FDA approves Pfizer’s pediatric vaccine.
2021 October 29: Canada’s NACI recommends mRNA booster for those who did not get mRNA.
2021 November 2: The CDC approves Pfizer’s pediatric vaccine.
2021 November 3: The World Health Organization approves Covaxin.
2021 November 9: Health Canada approves the regular (not lower dose) Comirnaty as an adult booster.
2021 November 18: Philippines grants emergency-use authorization to Novavax.
2021 November 19: Health Canada approves Pfizer’s pediatric vaccine.
2021 November 19: US FDA advisory board endorsed Pfizer or Moderna boosters for all adults.
2021 November 30: The Vietnamese gave up on the NDV-HXP-S trials because they had too much trouble finding volunteers.
2021 Dec 7: Medicago announces Ph3 results.
2021 Dec 10: US FDA approves Pfizer booster for 16 and 17 year-olds.
2021 Dec 17: World Health Organization approves Covovax, the version of Novavax made by Serum Institute of India (which means that COVAX can start distributing it).
2021 Dec 17: Pfizer’s vaccine for 2 to 5 year-olds didn’t provide adequate protection with two doses.
2021 Dec 20: EU gives conditional use approval to Novavax.
2021 Dec 27: India gives EUA to Corbevax and Covovax (SII’s Novavax).
2022 Jan 5: US CDC approves (and recommends) Pfizer booster for teens.
2022 Jan 12: Novavax approved in South Korea.
2022 Jan 19: Novavax granted provisional approval in Australia.
2022 Jan 25: NACI recommends that Canadian children 5-11 years old should get vaccinated; immunocompromised kids should get a booster.
2022 Jan 31: US FDA gives full approval to Moderna’s Spikevax.
2022 Jan 31: Novavax (FINALLY) requests approval from US FDA.
2022 Feb 10: Novavax finishes Phase 3 in adolescents.
2022 Feb 17: Health Canada approve Novavax for adults.
2022 Feb 23: Sanofi/GSK finish Phase 3.
2022 Feb 24: Canada approves Medicago.
2022 Feb 25: EU approves Moderna for kids 6-11 y/o.
2022 March 16: Pfizer/BNTech requests FDA approval for fourth dose for elderly.
2022 March 16: Health Canada approves Moderna for children 6-11.
2022 March 17: Moderna requests FDA approval for fourth dose for adults.
2022 April 14: UK approves Valneva.
2022 April 14: UK approves Moderna for kids 6-11.
2022 May 17: US FDA approves Pfizer booster for kids 5-11.
2022 May 23: Pfizer says 3 doses work well for kids under 5.
2022 June 2: Health Canada approves boosters for 16- and 17-year-olds.
2022 June 17: USA FDA approves Pfizer and Moderna shots for kids 6 months to 5 years old.
2022 June 23: USA approves Moderna for 6-17 year olds.
2022 June 28: India approves Gennova’s self-amplifying mRNA vaccine for emergency use.
2022 June 29: South Korea approves SK Bioscience/UW’s protein subunit vaccine.
2022 July 5: EU gives Novavax conditional approval for its vax for 12-17 year-olds.
2022 July 14: Canada approves Moderna for kids 6 months to 5 years old.
2022 July 20: US CDC approves Novavax.
2022 Aug 18: UK approves a BA.1-based Moderna vax.
2022 Aug 22: USA approves Emergency Use Authorization for Novavax for 12 to 17 year olds.
2022 Aug 31: USA FDA approves BA.5-based boosters from Pfizer and Moderna.
2022 Sep 1: Health Canada approves Moderna BA.1 boosters.
2022 Sep 1: EU approves Novavax as a booster for adults.
2022 Sep 1: USA CDC recommends BA.5 boosters from Pfizer and Moderna.
2022 Sep 9: Health Canada approves Pfizer for kids 6 months to to 5 years.
2022 Sep 12: EU approves Novavax as a booster.
2022 Sep 7: Health Canada approves Pfizer BA.5 booster for over-12s.
2022 Oct 12: US FDA approves BA.4/5 for 5-11 y/os.
2022 Oct 19: US FDA approves Novavax as a booster for adults.
2022 Nov 3: Health Canada approves Moderna BA.4/5 as an booster for over-18s.
2022 Nov 9: UK authorizes Novavax and bivalent BA.5 Pfizer as a boosters for adults.
2022 Nov 17: Canada authorises Novavax booster for over-12s.
2202 Nov 28: India give emergency use authorization iNCOVACC — a nasal vaccine — for both primary and booster.
2022 Dec 6: Health Canada approves Novavax as a primary series for 12-17 year-olds.
2022 Dec 7: China grants Emergency Use Authorization to SinoCellTech SCTV01C, Clover Biopharmaceuticals’ SCB-2019, Wantai BioPharm (nasal spray) and WestVac Biopharm’s Sf9.
2022 Dec 8: USA authorizes bivalent boosters down to age 6 months.
2022 Dec 9: Canada authorizes Pfizer’s BA.4/5 bivalent booster for kids 5-11.
2022 Dec 21: UK approves Sanofi/GSK vaccine.
2023 Jan 26: India approves Bharat Biotech’s nasal vaccine.
2023 May 26: UK approves SKYCovion/GBP510.
2023 June 21: India approved GEMCOVAC-OM self-amplifying mRNA vax.
2023 Sep 11: US approves Pfizer and Moderna’s XBB 1.5 booster.
2023 Sep 12: Canada approves Moderna’s XBB 1.5 booster.
2023 Sep 28: Canada approves Pfizer’s XBB 1.5 booster.
2023 Oct 3: US approves Novavax XBB 1.5 booster.
2023 Oct 31: EU approves Novavax XBB 1.5 booster.
2023 Nov 27: Japan approves self-amplifying vax ARCT-154 from Arcturus. This is the first next-generation vaccine approved by a country that the World Health Organization designates as “stringent”.
2023 Nov 29: World Health Organization approves Novavax XBB 1.5 vaccine.
2023 Nov 29: Korea approves Novavax XBB 1.5 vaccine.
2024 Jan 22: World Health Organization approves Emergency Use Authorization for CORBEVAX.
2024 Jan 24: UK approves Novava XBB 1.5 vaccine.
2024 Feb 16: Japan approves the first self-amplified RNA vaccine, LUNAR-COV19.
2024 Feb 23: Moderna finishes vax plant in Laval, Quebec.
2024 Jun 7: Moderna submits application to USA FDA for a JN.1-based vax.
2024 Jun 10: USA FDA requests that vaccine makers make JN.1-based fall doses.
2024 Jun 14: Novavax submits application to US FDA for JN.1 vaccine.
2024 Jun 20: USA FDA requests that vaccine makers make KP.2-based fall doses.
2024 Aug 22: USA approves Pfizer and Moderna KP.2 vaccines.
2024 Aug 30: USA approves Novavax JN.1 vaccine.
2024 Sep 3: UK approves Moderna’s JN.1 vaccine.
2024 Sep 13: Japan approves CSL and Arcturus’ self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE, based on JN.1.
2024-09-17: Health Canada approves Moderna KP.2 vaccine.
2024-09-19: Health Canada approves Novavax JN.1 vaccine.
2024-09-24: Health Canada approves Pfizer’s KP.2 vaccine.
2024-10-18: World Health Organization prequalifies HIPRA’s Bimervax.

(NB: I include the US’ FDA approval times in part because times are similar to the Canadian approval times.) It took ~4.5 months for Pfizer’s COVID vaccine and 5 months for Moderna from start to finish of the trial. Note that is really fast for a clinical trial, and was possible only because there were so many cases of COVID-19. (The faster people get sick, the faster you can see a difference between the control group and the vaccine group.) Subsequent trials might actually be faster because there is even more transmission.

See also the New York Times’ vaccine tracker for good information on all the vaccines which have gotten at least to Phase 1 human trials.

Hilda Bastain has a very in-depth look at all the vaccine trial results.